Repatha Gets Price Raise as It Wins Post-Launch Premium for CV Risk Reduction

Amgen Astellas BioPharma’s PCSK9 inhibitor Repatha (evolocumab) will get an NHI price raise in April 2018 as it clinched a post-launch price premium for “true clinical utility” thanks to cardiovascular risk reduction data yielded from its global FOURIER study. Buoyed...read more